Kroon C, ten Hove W R, de Boer A, Kroon J M, van der Pol J M, Harthoorn-Lasthuizen E J, Schoemaker H C, van der Meer F J, Cohen A F
Centre for Human Drug Research, University Hospital, Leiden, The Netherlands.
Circulation. 1992 Nov;86(5):1370-5. doi: 10.1161/01.cir.86.5.1370.
In this study, the anticoagulant response of 12,500 IU heparin s.c. was investigated in patients with myocardial infarction and healthy volunteers to determine variabilities in response and modifying factors.
On the fourth day after thrombolytic therapy, blood samples were taken before and at frequent intervals until 10 hours after the injection of 12,500 IU heparin s.c. Plasma anti-Xa activity, anti-IIa activity, and the activated partial thromboplastin time (APTT) were measured in addition to body weight and thickness of the abdominal subcutaneous fat layer. Contrary to expectations, the increase of anti-Xa activity, anti-IIa activity, and APTT compared with baseline (predrug) levels was very small, with an average maximal APTT of 42.6 seconds (SD, 12.4 seconds; range, 30.4-70.7 seconds). Subsequently, the influence of the length of the injection needle on the anticoagulant effect of 12,500 IU heparin s.c. was studied in 10 healthy volunteers to find a factor that could be responsible for the poor response in the patients. The length of the injection needle did not influence the anticoagulant effect of heparin. Large interindividual and intraindividual variabilities were seen in the volunteers. The majority of volunteers had minimal prolongation of the APTT, but very strong prolongation was also seen (maximal APTT, 163 seconds). There was no correlation between the abdominal skinfold thickness and anti-Xa activity, anti-IIa activity, or APTT (p > 0.05), but in the patient study, there was a correlation between weight and anti-Xa activity and anti-IIa activity (p < 0.05), and in the volunteer study, there was a correlation between weight and anti-Xa activity and APTT (p < 0.05).
Subcutaneous administration of heparin in a fixed dose for prophylactic and therapeutic purposes may be inadequate because of the large interindividual and intraindividual variations in anticoagulant effect.
在本研究中,对心肌梗死患者和健康志愿者皮下注射12500 IU肝素后的抗凝反应进行了研究,以确定反应的变异性和影响因素。
在溶栓治疗后的第四天,于皮下注射12500 IU肝素前及注射后频繁采集血样,直至10小时。除测量体重和腹部皮下脂肪层厚度外,还测定了血浆抗Xa活性、抗IIa活性及活化部分凝血活酶时间(APTT)。与预期相反,与基线(用药前)水平相比,抗Xa活性、抗IIa活性及APTT的增加非常小,APTT平均最大为42.6秒(标准差,12.4秒;范围,30.4 - 70.7秒)。随后,在10名健康志愿者中研究了注射针长度对皮下注射12500 IU肝素抗凝效果的影响,以寻找可能导致患者反应不佳的因素。注射针长度不影响肝素的抗凝效果。志愿者中观察到较大的个体间和个体内变异性。大多数志愿者的APTT延长最小,但也有非常明显的延长(最大APTT为163秒)。腹部皮褶厚度与抗Xa活性、抗IIa活性或APTT之间无相关性(p>0.05),但在患者研究中,体重与抗Xa活性及抗IIa活性之间存在相关性(p<0.05),在志愿者研究中,体重与抗Xa活性及APTT之间存在相关性(p<0.05)。
由于抗凝效果存在较大的个体间和个体内差异,皮下注射固定剂量肝素用于预防和治疗目的可能并不充分。